• linkedin
  • Increase Font
  • Sharebar

    Personalized Melanoma Vaccines Debut in Humans

    DT-eNews-Issue_402.jpg

    Identifying specific neo-antigens in melanoma, a cancer known for having high numbers of genetic mutations caused by exposure to ultraviolet light, is no easy task. A melanoma biopsy typically carries 500 or more mutated genes.

    To date, vaccines have targeted non-mutated shared proteins expressed in normal and cancer cells. This has made it difficult to stimulate a robust immune response because the immune system does not see these proteins as foreign, said senior author Gerald Linette, M.D., Ph.D., a Washington University medical oncologist.

    READ: Targeting your melanoma therapy

    Researchers recently published results on the first human study1 looking at personalized vaccines designed to activate T-cells aimed at individual cancer patient’s mutations. The study, including three advanced melanoma patients, suggests these tailor-made vaccines boost T-cell number and diversity, resulting in a tumor response.

    The vaccines in this study are engineered based on which of the tumor-specific proteins altered due to DNA mutations are most likely to elicit a strong individual immune responses, according to co-author Elaine Mardis, Ph.D., co-director of the McDonnell Genome Institute at Washington University.

    “In particular, our vaccine approach seeks to remind the patient's immune system that these mutated proteins are truly non-self…,” Mardis said.

    NEXT: Methodology

    Lisette Hilton
    Lisette Hilton is president of Words Come Alive, based in Boca Raton, Florida.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow